Endokrynologia Polska最新文献

{"title":"Carcinoid syndrome in neuroendocrine carcinoma mimicking Clostridioides difficile sepsis.","authors":"Jan Musiałkiewicz, Paweł Gut, Michał Olejarz, Adam Maciejewski, Paweł Komarnicki, Paulina Ziółkowska, Marek Ruchała","doi":"10.5603/ep.112481","DOIUrl":"https://doi.org/10.5603/ep.112481","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pituitary carcinoma: a diagnostic labyrinth in a rare endocrinopathy.","authors":"Julia Anita Tarnowska, Filip Szydzik, Bartosz Żegleń, Ewa Zalewska, Monika Berendt-Obołończyk, Sonia Kaniuka-Jakubowska, Michał Kunc, Joanna Kufel-Grabowska, Renata Świątkowska-Stodulska","doi":"10.5603/ep.108399","DOIUrl":"https://doi.org/10.5603/ep.108399","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 2","pages":"124-125"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomics and metabolomics reveal growth hormone deficiency-induced complement and metabolic dysregulation in post-COVID-19 condition.","authors":"Guirong Bai, Xiaomin Xie, Shiting Li, Wenrui Ji, Huan Li, Yanting He, Li Zhang, Ling Li, Siqi Pei, Yazhi Yang, Yawen Wu, Rui Ping","doi":"10.5603/ep.110845","DOIUrl":"10.5603/ep.110845","url":null,"abstract":"<p><strong>Introduction: </strong>Post-COVID-19 condition (PCC) is often accompanied by endocrine and immune dysregulation. Growth hormone (GH)deficiency has been reported in PCC patients, but its systemic effects remain poorly defined.</p><p><strong>Material and methods: </strong>Eighty-eight PCC patients were classified into four groups based on GH levels (A: GH ≥ 10 ng/mL; B:5 ng/mL ≤ GH < 10 ng/mL; C: 1 ng/mL ≤ GH < 5 ng/mL; D: GH < 1 ng/mL), and insulin tolerance testing was performed to assess GH and cortisol levels. Serum samples from PCC patients were analyzed using proteomics and metabolomics, followed by correlation analyseswith GH and cortisol levels.</p><p><strong>Results: </strong>There were significant differences among the four groups in GH levels at baseline, 30, 60, 90, and 120 minutes after ITT. Similarly, cortisol levels at 30, 60, 90, and 120 minutes post ITT also showed significant differences among the four groups. Proteomic profiling identifiedsignificant alterations of proteins in complement and coagulation cascades across different GH levels. Compared with group B, groupD (GH deficiency) showed reduced expression of lipid transport proteins (such as APOB, APOH, and APOF), consistent with the lowerserum low-density lipoprotein cholesterol (LDL-C) levels observed in the GH deficiency group. Integrative analysis of comparisons amonggroups highlighted SPARCL1 as a hub protein linked to GH dysregulation, showing a critical response to declining GH. Correlation analysisalso revealed strong associations of F/GH levels with complement-related proteins and SPARCL1. Metabolomic profiling revealed that L-glutamic acid and traumatic acid were significantly elevated in group C compared with group B, with AUC values of 0.657 and 0.739,respectively, indicating that these metabolites can distinguish patients with normal GH from those with GH deficiency. In addition, tetradecanedioicacid, which was markedly increased in group C compared to group D, showed a significant positive correlation with GHlevels at multiple time points. Integrated proteomic and metabolomic analyses further demonstrated significant associations betweendifferentially abundant proteins and metabolites.</p><p><strong>Conclusions: </strong>Our integrated proteomic-metabolomic analysis reveals that GH deficiency in PCC patients is associated with complement dysregulation, highlighting SPARCL1 as a potential biomarker of GH deficiency in PCC patients.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"156-171"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidogram profiles in patients with Graves' and Basedow's disease with and without orbitopathy.","authors":"Mariusz Nowak, Wojciech Nowak, Magdalena Londzin-Olesik, Bogdan Marek, Beata Kos-Kudła, Dariusz Kajdaniuk, Lucyna Siemińska, Jacek Karpe, Tomasz Wielkoszyński","doi":"10.5603/ep.108188","DOIUrl":"10.5603/ep.108188","url":null,"abstract":"<p><strong>Introduction: </strong>Researchers reported on the pathogenic role of hypercholesterolemia in thyroid orbitopathy (TO) and the use of statins in its prevention and treatment. To confirm these observations, we conducted a prospective study of patients with Graves' and Basedow's disease (GBD) to evaluate the relationship between the presence of TO and levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and apolipoproteins A1 and B (Apo A1, Apo B), along with the impact of immunosuppressive treatment on the lipid profile.</p><p><strong>Material and methods: </strong>Forty-seven patients with GBD diagnosed within the past 12 months were eligible for the study. In the GBD group, 31 patients were diagnosed with active TO and qualified for immunosuppressive treatment, while 16 patients did not have TO. TC, TG, HDL-C, and LDL-C levels were measured in serum using enzymatic methods, and Apo A-1 and Apo B levels were determined by immunoturbidimetric methods.</p><p><strong>Results: </strong>The mean TC concentration in patients with active TO who qualified for immunosuppressive treatment was 207.7 ± 42.7 mg/dL, significantly higher than the values in GBD patients without TO symptoms (191.5 ± 47.8 mg/dL). After completing immunosuppressive treatment, the mean TC concentration increased to 214.3 ± 49.8 mg/dL, remaining significantly higher than before treatment. The mean LDL-C concentration in patients with active TO was 131.6 ± 40.4 mg/dL and was higher, though not significantly, compared to the GBD group without TO symptoms (122.6 ± 49.0 mg/dL). After immunosuppressive treatment, the mean LDL-C levels increased to 142.1 ± 54.5 mg/dL and were also significantly higher than before treatment. Additionally, the mean Apo B concentration in patients with active TO was significantly higher than in patients without TO. After immunosuppressive treatment, the mean Apo B concentration increased and remained significantly higher than before treatment. There was no significant difference in HDL-C, Apo A1, and TG concentrations between the groups with and without TO, nor their levels after immunosuppressive treatment.</p><p><strong>Conclusions: </strong>The use of statins as adjunctive therapy in GBD patients with active TO qualified for immunosuppressive treatment is reasonable due to the increase in TC, LDL-C, and Apo B levels during treatment, as well as for their pleiotropic effects, including their anti-inflammatory effects.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"11-19"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asprosin, but not subfatin, associated with non-obese polycystic ovary syndrome.","authors":"Reha Baran, Suzan Tabur, Seyithan Taysı, Esma Gülsun Arslan Cellat","doi":"10.5603/ep.108447","DOIUrl":"10.5603/ep.108447","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a condition characterized by chronic hormonal and metabolic disturbances, commonly presenting with amenorrhea, hirsutism, and multiple ovarian cysts. Asprosin and subfatin are adipokines synthesized by adipose tissue and are associated with metabolic disorders. This study aimed to investigate these adipokines in normal-weight women with PCOS.</p><p><strong>Material and methods: </strong>A total of 60 normal-weight women were recruited in the study, including 30 diagnosed with PCOS according to the Rotterdam criteria and 30 healthy controls. Serum samples were collected on the third day of the menstrual cycle after an overnight fast in the morning. Demographic, metabolic, and hormonal parameters of the participants were subsequently analyzed.</p><p><strong>Results: </strong>In the PCOS group, levels of homeostatic model assessment of insulin resistance (HOMA-IR) index, insulin, asprosin, total testosterone, and Ferriman-Gallwey score were significantly higher compared with the control group. No significant difference was found in subfatin levels between the groups. Correlation analysis showed positive associations of asprosin with weight, body mass index (BMI), waist circumference, insulin, HOMA-IR, and C-reactive protein (CRP). In addition, receiver operating characteristic (ROC) analysis identified an asprosin cut-off value of 39.25 ng/mL, which yielded an area under the curve (AUC) of 0.760 [95% confidence interval (CI): 0.641-0.879], with a sensitivity of 66.7% and a specificity of 73.3% (p = 0.001). Furthermore, binary logistic regression analysis revealed that the plasma asprosin level was significantly correlated with PCOS in a model after controlling for age, BMI, and HOMA-IR [odds ratio (OR): 1.036, 95% CI: 1.000-1.073; p = 0.048], suggesting that asprosin could be an independent risk factor for PCOS.</p><p><strong>Conclusions: </strong>Asprosin, but not subfatin, was significantly elevated in non-obese women with PCOS. It may serve as a marker of PCOS independent of insulin resistance in normal-weight women.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"45-50"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emphysematous cystitis: an uncommon and severe complication of diabetes.","authors":"Krzysztof Nowakowski, Justyna Czarniecka, Stanisław Hartabus, Grzegorz Michno, Andrzej Potyka","doi":"10.5603/ep.108928","DOIUrl":"10.5603/ep.108928","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 1","pages":"87-88"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating obesity phenotype features in a real-world cohort - a non-interventional pilot study using an original questionnaire.","authors":"Jakub Gołacki, Paulina Gryń, Martyn Kępka, Magdalena Skorek, Paulina Terlecka, Monika Lenart-Lipińska, Beata Matyjaszek-Matuszek","doi":"10.5603/ep.112393","DOIUrl":"https://doi.org/10.5603/ep.112393","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a heterogeneous chronic disease, and phenotyping may support personalized management; however, referencephenotyping tools are difficult to implement in routine care.</p><p><strong>Material and methods: </strong>We conducted a retrospective real-world evidence analysis of 314 adults [206 women; mean age 48 years; mean body mass index (BMI) 38.30 ± 5.79 kg/m2] evaluated between November 2024 and May 2025 in a tertiary obesity care program. An originalquestionnaire was used to subjectively estimate phenotype features consistent with four obesity phenotypes (hungry gut, hungry brain,emotional eating, and slow burn) or their combinations. HbA1c and body composition were assessed by bioimpedance. The study wasnon-interventional and phenotype estimation did not guide pharmacotherapy selection.</p><p><strong>Results: </strong>In the whole cohort, no phenotype was identified in 158/314 patients (50.3%). As any-occurrence frequencies in the whole cohort, the most frequent estimated phenotype feature was slow burn (75/314, 23.9%), followed by emotional eating (66/314, 21.0%), hungry brain (52/314, 16.6%), and hungry gut (42/314, 13.4%). Because overlaps were allowed, phenotype frequencies represent any occurrenceand do not sum to 100%. The slow burn phenotype was associated with lower skeletal muscle mass (mean difference ~4.5 kg vs. otherphenotypes). Hungry gut occurred more frequently in individuals with HbA1c ≥ 6.5%, whereas hungry brain was least frequent in thatgroup; in patients with obesity and type 2 diabetes, higher HbA1c was associated with a greater number of estimated phenotype features.</p><p><strong>Conclusions: </strong>Questionnaire-based estimation of obesity phenotype features was feasible in routine care, but the high proportion ofundetermined cases indicates insufficient sensitivity for clinical use at the current stage. Therefore, LOPEQ should be regarded as an exploratory, hypothesis-generating tool requiring formal validation against objective reference methods before any treatment-guiding application.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 4","pages":"347-352"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal endometriosis mimicking Crohn's disease: a rare cause of nonspecific abdominal pain.","authors":"Julia Tarnowska, Patrycja Łazicka, Joanna Rymuza, Paulina Mądzik, Joanna Podgórska, Urszula Ambroziak","doi":"10.5603/ep.111168","DOIUrl":"10.5603/ep.111168","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"394-395"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148440515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Over 600 IU of insulin per day in a pregnant woman with congenital generalized lipodystrophy - clinical vignette.","authors":"Julia Piaśnik, Katarzyna Nabrdalik, Elżbieta Tabor, Janusz Gumprecht, Hanna Kwiendacz","doi":"10.5603/ep.111987","DOIUrl":"10.5603/ep.111987","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"390-391"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 5 diabetes mellitus: revisiting malnutrition-related diabetes.","authors":"Michalina Hryncewicz, Paulina Kostrzewska, Pawel Kuca, Roman Łaz, Anna Migda, Przemyslaw Witek","doi":"10.5603/ep.111734","DOIUrl":"10.5603/ep.111734","url":null,"abstract":"<p><p>A distinct form of diabetes occurring in lean, young individuals with a history of undernutrition was first described in the 1950s asa paradoxical combination of severe hyperglycemia, low body weight, and the absence of ketosis. Historically termed malnutrition-relateddiabetes mellitus (MRDM), it was recognized as a separate entity by the World Health Organization (WHO) in 1985 but was removedfrom formal classification in 1999 due to insufficient mechanistic evidence. Over the following two decades, research in low- and middle-income countries revealed unique metabolic traits of malnutrition-associateddiabetes, distinguishing it from type 1 and type 2 diabetes. In 2025, the International Diabetes Federation (IDF) formally endorsed recognitionof type 5 diabetes mellitus (T5DM), which is estimated to affect approximately 20-25 million people worldwide and predominantlyaffects young individuals with low body mass index living in low- and middle-income countries. T5DM is characterized by impaired insulin secretion, preserved insulin sensitivity, resistance to ketosis despite severe hyperglycemia, and absence of autoimmune markers. Early-life undernutrition is increasingly recognized as a factor disrupting pancreatic organogenesisand β-cell development, resulting in persistent structural deficits and limited functional β-cell reserve in adulthood. Effective management necessitates an integrated nutritional and pharmacological approach. Incorrectly classifying the condition as type 1diabetes may lead to unnecessary lifelong intensive insulin therapy, while misclassification as type 2 diabetes may lead to an inappropriatefocus on insulin resistance-targeted therapies. Although T5DM is most commonly reported in low- and middle-income countries, awareness is essential in high-income settings, particularly among migrant populations from regions affected by chronic undernutrition. Further research is needed to develop standardized diagnostic criteria, improve prevention strategies, and establish evidence-based treatment guidelines.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"77 4","pages":"283-291"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}